Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
By H. Hanai, T. Iida, K. Takeuchi, Fumitoshi Watanabe, Y. Maruyama, A. Andoh, T. Tsujikawa, Y. Fujiyama, K. Mitsuyama, M. Sata and 10 more. Clinical Gastroenterology and Hepatology, 2006
700 citations recorded by the source corpus.
Subfields: Analytical Chemistry, Genetics, Molecular Medicine
View Paper: https://www.semanticscholar.org/paper/c0a3e05f27fbe1ae17e9003da044887c01c8cf75
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Medicine
- Bharat B. Aggarwal
- A. Kunnumakkara
- S. Prasad
- N. Škalko-Basnet
- P. Basnet
- Devivasha Bordoloi
- N. Roy
- J. Monisha
Citations in the corpus
- Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases (2017, background): “Moreover, the curcumin treatment was also found to reduce the stiffness and swelling in the joints of patients with RA (Hanai et al., 2006).”
- Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer's Disease (2008, background): “In contrast to nonsteroidal anti-inflammatory drugs whose adverse side effects include gastrointestinal ulceration and liver or kidney toxicity, curcumin seems to be relatively safe, even in clinical trials for prevention of relapse of ulcerative colitis (Hanai et al., 2006).”
- Curcumin: An Anti-Inflammatory Molecule from a Curry Spice on the Path to Cancer Treatment (2011, background): “Subsequently, a randomized double-blind, placebo-controlled study was performed in patients with ulcerative colitis (UC) [109].”
- Upsides and Downsides of Reactive Oxygen Species for Cancer: The Roles of Reactive Oxygen Species in Tumorigenesis, Prevention, and Therapy (2012, unknown): “Curcumin also seems a promising and safe medication for maintaining remission in patients with quiescent ulcerative colitis (117).”
- Curcumin: Preventive and Therapeutic Properties in Laboratory Studies and Clinical Trials (2008, unknown): “Additionally, patients taking curcumin had an improved clinical activity index (CAI) and endoscopic index (EI), which were used to monitor disease activity objectively (101).”
- Curcumin as "Curecumin": from kitchen to clinic. (2008, background): “Ulcerative colitis 2000 mg/day 180 days 89 Low recurrence; improved symptoms [188] Familial adenomatous polyposis 480 mg; 3/day 180 days 5 Decrease in the number of polyps was 60.”